Phase IIIAstraZeneca's vaccine candidate is already in large-scale Phase II/III clinical trials after promising results in Phase I/II concerning safety and immunogenicity.
Advance purchaseAs with all these so-called advance purchase agreements, in which the EU offers guarantees against companies' development and manufacturing costs, the actual acquisition will take place only once the potential vaccine has proven to be safe and effective.
TRY APM HEALTH EUROPE AND GET ACCESS TO THE FULL CONTENT
Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations
Events coverage with a unique focus on Market Access & sustainability of healthcare systems
6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris
Ask for a Free trial and get access to the latest stories
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
an initial 10 day temporary access of APM Health Europe.